In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.

Hologic is down approximately 20% from recent highs and continues to grow organically and via a series of 'bolt-on' ...

Hologic HOLX is set to release first-quarter fiscal 2025 results on Feb. 5 after the closing bell. Stay up-to-date with all ...

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through ...

to the company’s GYN Surgical portfolio of products. Furthermore, the deal aligns with Hologic’s commitment to making minimally invasive treatment options more accessible for women.

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

The U.S. Food and Drug Administration has sent a warning letter to Marlborough, Mass.-based medical technology company ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on HOLX stock, giving a Buy rating on January 13.Stay Ahead of the ...

Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Hologic in a research note issued on ...

W ith a market cap of $18.9 billion, Marlborough, Massachusetts-based Hologic, Inc. focuses on diagnostics, imaging systems, and surgical products for women’s health.Through its four segments ...

Hologic, Inc.’s HOLX robust strength in the Surgical business is poised to drive growth in the upcoming quarters. The company's strategic initiatives look highly promising for the stock.